Skip to content

Cell Therapeutics’ Opaxio Receives FDA Orphan Drug Designation (ODD) For Brain Cancer

October 4, 2012

       Cell Therapeutics’ Opaxio receives FDA Orphan Drug Designation (ODD) on September 20, 2012 for the treatment of glioblastoma multiforme (GBM). In 2012 it is estimated that 10,000 – 12,000 cases are to be diagnosed in the US.

       Opaxio is a form of Paclitaxel, a chemotherapy drug. Opaxio delivers Paclitaxel to the tumors directly & reduces the drug amount that reaches healthy tissue.  


Bloomberg Businessweek News October 2, 2012 Article titled,”Cell Therapeutics rises on orphan drug decision” 

Cell Therapeutics October 2, 2012 News Release  

Copyright © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: